SIC
CMPX icon

SJS Investment Consulting’s Compass Therapeutics CMPX Stock Holding History

SJS Investment Consulting’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78K Buy
812
+785
+2,907% +$2.32K ﹤0.01% 1820
2026
Q1 		$143 Hold
27
– – ﹤0.01% 2062
2025
Q4 		$145 Buy
+27
New +$125 ﹤0.01% 1884

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SJS Investment Consulting's CMPX Position: Q2 2026 in Review

SJS Investment Consulting increased its Compass Therapeutics (CMPX) stake by 2,907% in Q2 2026, buying an estimated $2.32K and bringing the position to 812 shares worth $1.78K. The position accounts for ﹤0.01% of the portfolio, ranked #1820.

SJS Investment Consulting first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • SJS Investment Consulting held 812 shares of Compass Therapeutics worth $1.78K as of Q2 2026.
  • SJS Investment Consulting bought 785 Compass Therapeutics shares in Q2 2026, an estimated $2.32K.
  • Compass Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1820 holding.
  • SJS Investment Consulting first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.